Dataset Information

PD-1⁺ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.

ABSTRACT: PD-1 blockade is a cancer immunotherapy effective in various types of cancer. In a fraction of treated patients, however, it causes rapid cancer progression called hyperprogressive disease (HPD). With our observation of HPD in ∼10% of anti-PD-1 monoclonal antibody (mAb)-treated advanced gastric cancer (GC) patients, we explored how anti-PD-1 mAb caused HPD in these patients and how HPD could be treated and prevented. In the majority of GC patients, tumor-infiltrating FoxP3^highCD45RA^-CD4⁺ T cells [effector Treg (eTreg) cells], which were abundant and highly suppressive in tumors, expressed PD-1 at equivalent levels as tumor-infiltrating CD4⁺ or CD8⁺ effector/memory T cells and at much higher levels than circulating eTreg cells. Comparison of GC tissue samples before and after anti-PD-1 mAb therapy revealed that the treatment markedly increased tumor-infiltrating proliferative (Ki67⁺) eTreg cells in HPD patients, contrasting with their reduction in non-HPD patients. Functionally, circulating and tumor-infiltrating PD-1⁺ eTreg cells were highly activated, showing higher expression of CTLA-4 than PD-1^- eTreg cells. PD-1 blockade significantly enhanced in vitro Treg cell suppressive activity. Similarly, in mice, genetic ablation or antibody-mediated blockade of PD-1 in Treg cells increased their proliferation and suppression of antitumor immune responses. Taken together, PD-1 blockade may facilitate the proliferation of highly suppressive PD-1⁺ eTreg cells in HPDs, resulting in inhibition of antitumor immunity. The presence of actively proliferating PD-1⁺ eTreg cells in tumors is therefore a reliable marker for HPD. Depletion of eTreg cells in tumor tissues would be effective in treating and preventing HPD in PD-1 blockade cancer immunotherapy.

SUBMITTER: Kamada T

PROVIDER: S-EPMC6525547 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

PD-1<sup>+</sup> regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.

Kamada Takahiro T Togashi Yosuke Y Tay Christopher C Ha Danbee D Sasaki Akinori A Nakamura Yoshiaki Y Sato Eiichi E Fukuoka Shota S Tada Yasuko Y Tanaka Atsushi A Morikawa Hiromasa H Kawazoe Akihito A Kinoshita Takahiro T Shitara Kohei K Sakaguchi Shimon S Nishikawa Hiroyoshi H

Proceedings of the National Academy of Sciences of the United States of America 20190426 20

PD-1 blockade is a cancer immunotherapy effective in various types of cancer. In a fraction of treated patients, however, it causes rapid cancer progression called hyperprogressive disease (HPD). With our observation of HPD in ∼10% of anti-PD-1 monoclonal antibody (mAb)-treated advanced gastric cancer (GC) patients, we explored how anti-PD-1 mAb caused HPD in these patients and how HPD could be treated and prevented. In the majority of GC patients, tumor-infiltrating FoxP3<sup>high</sup>CD45RA<s ...[more]

PMID: 31028147

Similar Datasets

Project description:BackgroundSystemic radiation treatments that preferentially irradiate cancer cells over normal tissue, known as targeted radionuclide therapy (TRT), have shown significant potential for treating metastatic prostate cancer. Preclinical studies have demonstrated the ability of external beam radiation therapy (EBRT) to sensitize tumors to T cell checkpoint blockade. Combining TRT approaches with immunotherapy may be more feasible than combining with EBRT to treat widely metastatic disease, however the effects of TRT on the prostate tumor microenvironment alone and in combinfation with checkpoint blockade have not yet been studied.MethodsC57BL/6 mice-bearing TRAMP-C1 tumors and FVB/NJ mice-bearing Myc-CaP tumors were treated with a single intravenous administration of either low-dose or high-dose 90Y-NM600 TRT, and with or without anti-PD-1 therapy. Groups of mice were followed for tumor growth while others were used for tissue collection and immunophenotyping of the tumors via flow cytometry.Results90Y-NM600 TRT was safe at doses that elicited a moderate antitumor response. TRT had multiple effects on the tumor microenvironment including increasing CD8 +T cell infiltration, increasing checkpoint molecule expression on CD8 +T cells, and increasing PD-L1 expression on myeloid cells. However, PD-1 blockade with TRT treatment did not improve antitumor efficacy. Tregs remained functional up to 1 week following TRT, but CD8 +T cells were not, and the suppressive function of Tregs increased when anti-PD-1 was present in in vitro studies. The combination of anti-PD-1 and TRT was only effective in vivo when Tregs were depleted.ConclusionsOur data suggest that the combination of 90Y-NM600 TRT and PD-1 blockade therapy is ineffective in these prostate cancer models due to the activating effect of anti-PD-1 on Tregs. This finding underscores the importance of thorough understanding of the effects of TRT and immunotherapy combinations on the tumor immune microenvironment prior to clinical investigation.

Dataset Information

PD-1⁺ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.

Publications

PD-1<sup>+</sup> regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.

Publications

PD-1<sup>+</sup> regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

PD-1⁺ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.